Coherus Biosciences Inc (CHRS) Is Looking To Compete With Amgen, Inc. (AMGN)’s Cancer Blockbuster
The biosimilar space is relatively young.
Posts Tagged ‘NASDAQ:AMGN’
Glaxis Capital All-In on These Two Stocks After Slashing Portfolio
Paul Holland and Matthew Miller co-founded Glaxis Capital in 2005. The fund's equity portfolio has remained fairly concentrated since the end of March last year.
Can The Top 10 S&P 500 Dividend Growers Continue Their Rapid Dividend Growth?
The ten S&P 500 companies that have increased their dividend payout by the highest average annual rate during the last five years are analyzed in this article.
Marten Transport Ltd (MRTN), Amgen Inc. (AMGN) and Parker-Hannifin Corp (PH) Witness Striking Insider Selling
There are various reasons why corporate insiders might sell shares of their own companies.
Billionaire Dan Loeb’s Top Picks Register Disappointing Returns
Billionaire Daniel S. Loeb founded activist hedge fund Third Point LLC in 1995.
Should You Avoid Amgen, Inc. (AMGN)?
The market has been volatile as the Federal Reserve winds down its easy money policies.
Hedge Funds Love These Biotech Stocks
Biotech has undoubtedly been one of the most cherished industries, among hedge funds over the last few years and it's not hard to understand why.
Why Are Investors Piling Into These Five Stocks?
With crude futures failing to rally past a key technical resistance level, shares of Sunedison Inc (NYSE:SUNE), SolarCity Corp (NASDAQ:SCTY),Solaredge Technologies Inc (NASDAQ...
Amgen, Inc. (AMGN): Are Hedge Funds Right About This Stock?
The market has been volatile as the Federal Reserve winds down its easy money policies.
Billionaire Dan Loeb’s Top Picks For A Fourth Quarter Recovery
Billionaire activist investor Dan Loeb of Third Point saw his hedge fund post losses of 8.9% for the September quarter in comparison to the S&P 500's slide of 6.4% during the ...
Billionaire Dan Loeb Grows Bearish on the Market As Short Positions Outpace His Conviction Buys
Billionaire investor Dan Loeb, the founder of activist hedge fund Third Point LLC, discussed the performance of his investment firm, including the broader market conditions ...
Sivik Global Healthcare’s Top Biotech Stock Picks For Q4
Sivik Global Healthcare is a Greenwich, Connecticut-based healthcare-focused hedge fund founded by Krishen Sud in 2006.
Billionaire Activist Dan Loeb Loses Money in Q3 but Remains Bullish on Stock Picks
When it comes to activist investing, Dan Loeb is one of the best in the business, generating strong returns through pushing companies to implement changes that maximize shareholder...
AbbVie, Biogen, Gilead: Smart Money Got Burned Betting on Biotech in Q3
When it rains, it pours, and for big pharma, it certainly poured in the third quarter.
5 Best Stocks To Buy According To 4 Billionaire Quants
What are the best stocks to buy? The Wisdom of Crowds: Why the Many Are Smarter Than The Few and How Collective Wisdom Shapes Business, Economies, Societies and Nations is James...
Five Best Stocks to Buy According To Quant Billionaires
One of the best ways to pick high-performing stocks is to follow the industry leaders and find out their stock investments.
Billionaire Dan Loeb Slightly Shuffles Third Point’s Top Picks, Selling Off Large Alibaba Group Holding Ltd (BABA) Stake
Famous billionaire activist hedge-fund manager Dan Loeb of Third Point is renowned for the bombshells that he drops on the management of his target companies in the form of letters...
United Therapeutics Corporation (UTHR), Amgen, Inc. (AMGN): Neil Shah’s Top Healthcare Picks Dominated S&P 500 Index in January-March
March Altus Capital Management, headquartered in Greenwich, Connecticut, was founded by Neil Shah in December 2011.This healthcare focused fund follows bottom-up fundamental analysis...
Ariad Pharmaceuticals, Inc. (ARIA), Amgen, Inc. (AMGN): How Sarissa Capital’s Top Picks Beat the Market
Headquartered in Connecticut, Sarissa Capital Management was founded by Alexander J. Denner in 2012. Prior to this, Mr.
Huge Losses in Alibaba Group Holding Ltd (BABA) Not Enough to Stop Billionaire Dan Loeb from Beating the Market
Considering that the second-largest holding of Dan Loeb's Third Point, Alibaba Group Holding Ltd (NYSE:BABA), lost 19.92% of its stock value during the first quarter, the fund...
Healthcare Hedge Fund Orbimed’s Top Picks and New Move
According to a Schedule 13D form filed yesterday with the Securities and Exchange Commission, Samuel Islay's Orbimed Advisors has slashed its stake in Intercept Pharmaceuticals...
Gilead Sciences, Inc., Amgen, Inc., Biogen Idec Inc Among Billionaires’ 5 Hottest Biotech Picks
With the high volatility prevalent in the biotechnology sector, investors have a hard time picking the right stocks to invest in.
Ariad Pharmaceuticals, Inc., Quest Diagnostics Inc, Amgen, Inc.: Sarissa Capital’s Top Stock Picks and New Moves
Alex Denner’s Sarissa Capital Management recently disclosed its stock picks for the fourth quarter of 2014 in a 13F Form filed with the U.S.
Billionaire Dan Loeb`s Third Point Looks to Rebound From Poor Year With Top Picks: Alibaba Group Holding Ltd (BABA), Amgen, Inc. (AMGN), Dow Chemical Co (DOW)
Dan Loeb`s Third Point filed its latest 13F with the SEC last week, detailing its long positions at the end of a self-admittedly poor year for the fund.
Amgen, Inc. (AMGN)’s Drug Trial Fails To Live Up To Expectation
Shares of Amgen, Inc.
Amgen, Inc. (AMGN) Announces Revenue Growth And Profitability In The Second Quarter
Amgen, Inc. (NASDAQ:AMGN) announced its second quarter financial results on July 29, 2014. Amgen's total revenues increased by 11% on the year to $5.18 billion.
Stuart Weisbrod’s Iguana Healthcare Management Is Fond of These Stocks
New York City-based Iguana Healthcare Management was founded by Stuart Weisbrod in 2010.
Is PowerShare Buyback Achievers Fund a Buy? The Safest Way To Profit From $455 Billion In Stock Buybacks
Over the past few years at StreetAuthority, we've been chronicling the remarkable pace of share buybacks.
Amgen, Inc. (AMGN)’s Potential Promise
Last Friday, Zacks released a new report were it reconfirmed its neutral rating for Amgen, Inc. (NASDAQ:AMGN).
Omthera Pharmaceuticals Inc (OMTH), Elan Corporation, plc (ADR) (ELN), Onyx Pharmaceuticals, Inc. (ONXX): 3 Big Biotech Buyouts of 2013
The Chinese calendar says 2013 is the year of the snake, but the market says it's the year of biotech.
Amgen, Inc. (AMGN), Impax Laboratories Inc (IPXL): Keryx Biopharmaceuticals (KERX)’s Stifel Conference Presentation
There were definitely some good parts in what Keryx Biopharmaceuticals (NASDAQ:KERX) had to say at this week's Stifel Nicolaus Weisel Healthcare Conference in Boston.
Bristol Myers Squibb Co. (BMY), Merck & Co., Inc. (MRK): Is AstraZeneca plc (ADR) (AZN)’s Recent Acquisition Bigger Than Onyx?
AstraZeneca plc (ADR) (NYSE:AZN) may have missed out on acquiring the oncology platform of Onyx Pharmaceuticals, but it responded by pulling the trigger on a $500 million deal...
Amgen, Inc. (AMGN), Teva Pharmaceutical Industries Ltd (ADR) (TEVA): The Neulasta Question
In a couple of years, Amgen, Inc. (NASDAQ:AMGN) will have to face the music when the patent for its $4 billion a year drug, Neulasta, expires in the U.S. and Europe.
Aegerion Pharmaceuticals, Inc. (AEGR): Cheers and Jeers for Amgen, Inc. (AMGN)’s Pipeline
Just after the successful acquisition of Onyx Pharmaceuticals and positive results on AMG-145, a cholesterol-lowering experimental drug, Amgen, Inc.
Pfizer Inc. (PFE), Regeneron Pharmaceuticals Inc (REGN), Amgen, Inc. (AMGN): Invest in the Next Biotech Frontier
The last several months have been remarkably exciting in the biotech space.
Cytokinetics, Inc. (CYTK), Amgen, Inc. (AMGN): Digging Deeper Into This Heart Failure Drug’s Miss
Before the market opened last Tuesday, Cytokinetics, Inc. (NASDAQ:CYTK) and Amgen, Inc.
Alexion Pharmaceuticals, Inc. (ALXN), Amgen, Inc. (AMGN), Baxter International Inc. (BAX): The Treatment of Rare Diseases Offers Unique Opportunities
A company with a modus operandi of tackling rare and very rare diseases might not necessarily jump out as a great investment, but this company has banked more than a billion...
MiMedx Group Inc (MDXG), Cytokinetics, Inc. (CYTK), Amgen, Inc. (AMGN): A Trio of Horrendous Health-Care Stocks This Week
College football arrived in a big way over the past week or so, with plenty of big plays already.
Astex Pharmaceuticals, Inc. (ASTX) Becomes the Latest Biotech Domino to Fall
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) is being scooped up by Tokyo-based Otsuka Pharmaceuticals.
Pfizer Inc. (PFE), Merck & Co., Inc. (MRK): Two Reasons This Biotech Hardly Moved After a Successful Trial
Adding Esperion Therapeutics' ECT-1002 to Pfizer Inc. (NYSE:PFE)'s Lipitor lowered bad LDL cholesterol levels by 22%.
Eli Lilly & Co. (LLY), Amgen, Inc. (AMGN), Merck & Co., Inc. (MRK): Where We’re Headed
Over the past couple of months we've discussed many of the biggest risk factors associated with some of the leading causes of death in the United States -- heart disease, cancer...
Amgen, Inc. (AMGN), Astex Pharmaceuticals, Inc. (ASTX), Pharmacyclics, Inc. (PCYC): This Week in Biotech
With the SPDR S&P Biotech Index up 35% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Celgene Corporation (CELG), Cytokinetics, Inc. (CYTK), Astex Pharmaceuticals, Inc. (ASTX): Is the Biotech Bubble About to Burst?
"Bubble" can be a provocative word in investing circles. Think of all that comes to mind when you hear it -- perhaps other words like over-hyped, overvalued, risky, etc.
Amgen, Inc. (AMGN), Onyx Pharmaceuticals, Inc. (ONXX): Monday’s Best Stocks
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Amgen, Inc. (AMGN), Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Onyx Pharmaceuticals, Inc. (ONXX): This Biotech Envisions Green
After a second offer, Amgen, Inc. (NASDAQ:AMGN) and Onyx Pharmaceuticals, Inc.
The Amgen, Inc. (AMGN)-Onyx Pharmaceuticals, Inc. (ONXX) Deal Should Make All Biotech Investors Happy
While that's certainly not what Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) investors were hoping for -- at one point, after Amgen, Inc.
Amgen, Inc. (AMGN), Onyx Pharmaceuticals, Inc. (ONXX), NASDAQ OMX Group, Inc. (NDAQ): Deals, Not Data, Drive Dow Today
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing...
Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Amgen, Inc. (AMGN): Is Galena Biopharma Inc (GALE)’s Big Break Just Around the Corner?
Judging by the numbers, Galena Biopharma Inc (NASDAQ:GALE) isn't exactly a stock many would call great.
